These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8452105)

  • 1. Phase II trials of tetrahydropyranyl-adriamycin (Pirarubicin) on renal and colon carcinoma, melanoma, and soft tissue sarcoma.
    Roché H; Guiochet N; Kerbrat P; Rebattu P; Fargeot P; Cattan A; Armand JP; Keiling R; Lentz MA; Van Glabeke M
    Am J Clin Oncol; 1993 Apr; 16(2):137-9. PubMed ID: 8452105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
    Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer.
    Chevallier B; Mignot L; Delozier T; Morvan F; Ferme C; Herait P
    Am J Clin Oncol; 1992 Oct; 15(5):395-8. PubMed ID: 1524040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
    Chawla SP; Papai Z; Mukhametshina G; Sankhala K; Vasylyev L; Fedenko A; Khamly K; Ganjoo K; Nagarkar R; Wieland S; Levitt DJ
    JAMA Oncol; 2015 Dec; 1(9):1272-80. PubMed ID: 26378637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas.
    Grenader T; Goldberg A; Hadas-Halperin I; Gabizon A
    Anticancer Drugs; 2009 Jan; 20(1):15-20. PubMed ID: 19342997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A pilot study of high-dose zorubicin in advanced stages of soft tissue sarcoma in adults].
    Jelić S; Tomasević Z; Kreacić M; Kovcin V; Radosavljević D; Vlajić M
    Bull Cancer; 1996 Dec; 83(12):1002-7. PubMed ID: 9116363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma.
    Sridhar KS; Hussein AM; Benedetto P; Ardalan B; Savaraj N; Richman SP
    Cancer; 1992 Sep; 70(6):1591-7. PubMed ID: 1516010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma.
    Braich TA; Salmon SE; Robertone A; Alberts DS; Jones SE; Miller TP; Garewal HS
    Invest New Drugs; 1986; 4(3):269-74. PubMed ID: 3818231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
    Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aclacinomycin A. Phase II evaluation in advanced soft tissue sarcoma.
    Pazdur R; Samson MK; Baker LH
    Am J Clin Oncol; 1987 Jun; 10(3):237-9. PubMed ID: 3473924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial.
    Jones RL; Wagner AJ; Kawai A; Tamura K; Shahir A; Van Tine BA; Martín-Broto J; Peterson PM; Wright J; Tap WD
    Clin Cancer Res; 2021 Jul; 27(14):3861-3866. PubMed ID: 33632930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of pirarubicin in the treatment of advanced pancreatic cancer.
    Mahjoubi M; Rougier P; Oliviera J; Herait P; Tigaud JM; Droz JP
    Cancer Invest; 1994; 12(4):403-5. PubMed ID: 8032961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.
    Chawla SP; Chua VS; Hendifar AF; Quon DV; Soman N; Sankhala KK; Wieland DS; Levitt DJ
    Cancer; 2015 Feb; 121(4):570-9. PubMed ID: 25312684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
    Bui BN; Chevallier B; Chevreau C; Krakowski I; Peny AM; Thyss A; Maugard-Louboutin C; Cupissol D; Fargeot P; Bonichon F
    J Clin Oncol; 1995 Oct; 13(10):2629-36. PubMed ID: 7595717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiotoxicity due to prolonged administration of THP (2"R-4'-O-tetrahydropyranyl-adriamycin)].
    Suzuki M; Hirono M; Majima H
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1993-9. PubMed ID: 9350248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of pirarubicin in the treatment of advanced bladder cancer.
    Mahjoubi M; Kattan J; Ghosn M; Droz JP; Philippot I; Herait P
    Invest New Drugs; 1992 Nov; 10(4):317-21. PubMed ID: 1487407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).
    Chauvergne J; Fumoleau P; Cappelaere P; Metz R; Armand JP; Chevallier B; Kerbrat P; de Forni M; Lhommé C; Roche H
    Eur J Cancer; 1993; 29A(3):350-4. PubMed ID: 8398333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
    Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
    Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.